HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia.

Abstract
A 77-year-old man who developed pancytopenia was administered granulocyte colony-stimulating factor (G-CSF) by another doctor, and referred to us for the evaluation of pancytopenia. He had hepatocellular carcinoma and was treated with transcatheter arterial chemoembolization (TACE) containg epirubicin (total dose: 300 mg over the last two years). Bone marrow aspiration smear demonstrated hypercellular marrow with promyelocytes. Cytogenetic analysis demonstrated del(7), t(15;17)(q22;q12), and a fluorescence in-situ hybridization (FISH) study demonstrated chimeric fusion genes of PML-RAR-alpha. He was diagnosed with therapy-related acute promyelocytic leukemia (APL), and treated with all trans-retinoic acid (ATRA). He showed the progressive accumulation of ascites with liver damage, without pulmonary symptoms of ATRA differentiation syndrome. After 60 days of ATRA treatment, complete hematological and cytogenetic responses were achieved. However, the patient died of septic circulatory failure.
AuthorsMunehiro Suzukawa, Tatsuki Nakazora, Yasufumi Kawasaki, Takayuki Tominaga, Kenji Shinohara
JournalInternal medicine (Tokyo, Japan) (Intern Med) Vol. 49 Issue 5 Pg. 457-60 ( 2010) ISSN: 1349-7235 [Electronic] Japan
PMID20190483 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Epirubicin
  • Tretinoin
Topics
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Ascites (chemically induced, diagnosis)
  • Carcinoma, Hepatocellular (therapy)
  • Chemoembolization, Therapeutic (adverse effects)
  • Epirubicin (administration & dosage)
  • Humans
  • Leukemia, Promyelocytic, Acute (drug therapy, etiology)
  • Liver Neoplasms (therapy)
  • Male
  • Tretinoin (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: